Methylation modification-based tumor marker stamp-ep6
AssigneeShanghai Epiprobe Biotechnology Co., Ltd.
InventorsZhenyan LI, Shihua DONG
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of disease diagnosis markers, and provides a methylation tumor marker STAMP-EP6, and an application thereof. The present invention provides an application of the methylation tumor marker STAMP-EP6 in preparing a cancer diagnosis reagent.
Claims23
1-4. (canceled)
A method for detecting a tumor, wherein said method comprises:
- detecting a modification on the CpG site(s) of a polynucleotide by a tumor detection agent or kit, if the hypermethylation of a subject is detected, the subject can be identified as having a high-risk of tumor;
- wherein said polynucleotide comprises:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1;
- (b) a fragment of the polynucleotide of (a), having at least one CpG site with modification;
- and/or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b).
A method of preparing a tumor detection agent, comprising:
- providing a polynucleotide, designing a detection agent for specifically detecting the modification on CpG(s) of the a target sequence which is the full length or fragment of the polynucleotide;
- wherein, said polynucleotide comprises:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1;
- (b) a fragment of the polynucleotide of (a), having at least one CpG site with modification;
- and/or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b).
(canceled)
The method according to claim 12, wherein the primers are:
- primers shown in SEQ ID NO:
- 5 and 6;
- or
- primers shown in SEQ ID NO:
- 7 and 8.
(canceled)
A detection kit, comprising:
- container(s) and a detection agent in the container(s);
- wherein said detection agent specifically detects the modification of the CpG(s) of a target sequence which is the full length or fragment of the polynucleotide;
- wherein said polynucleotide comprises:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1;
- (b) a fragment of the polynucleotide of (a), having at least one CpG site with modification;
- and/or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b).
A method of detecting the methylation profile of a sample in vitro, comprising:
- (i) providing the sample and extracting nucleic acid;
- (ii) detecting a modification on CPG site(s) of a target sequence in the nucleic acid of (i), wherein the target sequence is a polynucleotide comprising:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1;
- (b) a fragment of the polynucleotide of (a), having at least one CpG site with modification;
- and/or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b).
The method according to claim 1, wherein said tumor detection agent or kit is specifically detect the polynucleotide, or the panel or gene group containing the polynucleotide.
The method according to claim 1, wherein said modification comprises 5-methylation, 5-hydroxymethylation, 5-formylcytosine or 5-carboxylcytosine.
An isolated polynucleotide, wherein the isolated polynucleotide comprises:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1 or a fragment thereof, having at least one CpG site with modification;
- said modification comprises 5-methylation, 5-hydroxymethylation, 5-formylcytosine or 5-carboxylcytosine;
- and/or
- (b) a nucleic acid complementary to the polynucleotide or fragment of (a).
An isolated polynucleotide, wherein the polynucleotide is converted from an original polynucleotide, said original polynucleotide comprises:
- (a) a polynucleotide with a nucleotide sequence as shown in SEQ ID NO:
- 1;
- (b) a fragment of the polynucleotide of (a), having at least one CpG site with modification;
- and/or (c) a nucleic acid complementary to the polynucleotide or fragment of (a) or (b);
- and as compared with the sequence of the original polynucleotide, cytosine C of the CpG site(s) with modification is unchanged, and the unmodified cytosine is converted into T or U in the converted polynucleotide.
Dependencies are inferred from the claim text.